Keyphrases
Randomized Placebo-controlled Trial
100%
Migraine Attack
100%
Calcitonin Receptor
100%
Cromakalim
100%
ATP-sensitive Potassium Channel
100%
Placebo
83%
Erenumab
33%
Placebo-controlled
16%
Trial Registration
16%
Observation Period
16%
Between-day
16%
Migraine without Aura (MWoA)
16%
Area under the Curve
16%
Superficial Temporal Artery
16%
Migraine
16%
Headache Intensity
16%
KATP Channel
16%
Receptor Activation
16%
Subcutaneous Injection
16%
Two-way Crossover
16%
CGRP Receptor
16%
KATP Channel Opener
16%
CGRP Receptor Antibody
16%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Migraine
100%
Calcitonin Gene Related Peptide Receptor
100%
Adenosine Triphosphate Sensitive Potassium Channel
100%
Lemakalim
85%
Erenumab
28%
Headache
14%
Migraine without Aura
14%
Channel Opener
14%
Subcutaneous Injection
14%
Receptor Antibody
14%
Neuroscience
Placebo
100%
Migraine
100%
Calcitonin Gene-Related Peptide Receptor
100%
Adenosine Triphosphate Sensitive Potassium Channel
100%
Erenumab
28%
Crossover Study
14%
Headache
14%
Superficial Temporal Artery
14%
Auras
14%
Receptor Antibody
14%